OZ.VGI.CO.ID - A new synthetic opioid, identified as cychlorphine, is increasingly capturing the attention of law enforcement and public health officials due to its purported potency and rapid emergence within the illicit drug supply. While some reports suggest it could be significantly more powerful than fentanyl, experts and harm reduction advocates emphasize the need for measured reporting and continued vigilance in addressing the evolving landscape of synthetic drugs.
Understanding Cychlorphine and Its Origins
Cychlorphine, chemically known as N-Propionitrile chlorphine, belongs to a novel class of synthetic opioids termed "orphines." This class represents the latest development in the ongoing waves of the U.S. opioid crisis, a public health emergency that has seen successive classes of illicit drugs gain prominence as others face increased regulatory pressure or market displacement.
The U.S. drug supply first encountered cychlorphine in 2024, according to the Center for Forensic Science Research & Education (CFSRE).
Later that same year, the Drug Enforcement Administration (DEA) reported its initial detection within the United States following an encounter at a Florida laboratory.
This marked the formal introduction of orphines into the U.S. drug market.
The Evolving Waves of the Opioid Crisis
To contextualize the emergence of cychlorphine, it is helpful to understand the historical progression of the U.S. opioid crisis, as outlined by the Centers for Disease Control and Prevention (CDC).
- First Wave (1990s): Characterized by a significant increase in opioid prescriptions, notably following the introduction of OxyContin by Purdue Pharma in 1995.
- Second Wave (2010 onwards): Saw a surge in heroin use, driven by more efficient distribution channels and the tightening of regulations on prescription opioids.
- Third Wave (2013 onwards): Marked by a dramatic rise in overdose deaths involving illicit synthetic opioids like fentanyl. Initially used in clinical settings, fentanyl began to be widely integrated into the illicit market, often sold as heroin or as counterfeit pills mimicking prescription drugs.
Following intensified global efforts to curb fentanyl production and distribution, a group of potent synthetic opioids known as nitazenes began to gain traction in the illicit market starting around 2019.
The DEA classified isotonitazene as a Schedule I substance in 2020, and subsequently scheduled seven other nitazenes.
In 2026, China implemented a broad ban on nitazenes, further prompting the emergence of substances like orphines as potential replacements in both U.S. and international markets.
Potency Concerns and Regulatory Response
Concerns regarding cychlorphine's potency have been a significant driver of recent warnings.
DEA officials have stated that the drug could be up to 10 times stronger than fentanyl.
While definitive, human-verified data is limited, Dr.
Shan Yin, a board member of the American College of Medical Toxicology, suggests that this potency claim is likely an estimate based on pharmacological profiles of similar compounds.
"This is not like a marketed drug where you could [administer it to] humans to determine what doses produce the same level of analgesia," Dr.
Yin explained to Rolling Stone, underscoring the challenges in precisely quantifying such potency outside of laboratory settings.
In response to these concerns, the DEA issued an emergency order in August 2026, placing cychlorphine and three related orphine analogs into Schedule I of the Controlled Substances Act.
This classification signifies a high potential for abuse and no accepted medical use, making research and access significantly more challenging.
Impact on the Illicit Drug Supply and Fatalities
The specter of cychlorphine has cast a shadow over public health messaging.
In April 2026, San Francisco health officials issued a warning after a reported fatal overdose.
The New York Times identified the victim as 16-year-old Dante Lacourte, whose autopsy confirmed cychlorphine as the cause of death.
His mother, Christina Lacourte, administered two doses of Narcan (naloxone) without success.
Statistical data, though still developing, indicates a concerning trend.
An April 30, 2026, alert from the Office of National Drug Control Policy (ONDCP) linked 55 deaths nationally to cychlorphine between 2025 and early 2026.
In Tennessee, the Knox County Regional Forensic Center (RFC) reported 63 deaths associated with the drug between July 2025 and September 2026 alone.
These figures highlight the growing presence of cychlorphine in fatal overdose cases.
Challenges in Detection and Overdose Reversal
A significant challenge posed by cychlorphine is its potential to evade detection by standard drug-checking tools.
Mike Selick, director of capacity building and community mobilization with the National Harm Reduction Coalition, noted that "standard test strips can’t detect the newer cychlorphine." This lack of detectability means that cychlorphine could be present in various illicit substances, including fentanyl, cocaine, and counterfeit pills, without users' knowledge.
Reports suggesting naloxone's ineffectiveness against cychlorphine overdoses have circulated, though experts caution against this interpretation.
Dr.
Darinka Mileusnic-Polchan of the Knox County Regional Forensic Center stated in a February 2026 press release that Narcan "does not completely block the effects of the drug and multiple doses may be needed." Chris Thomas, director of the RFC, later clarified to Filter magazine that this information originated from federal officials' discussions with DEA toxicologists, who indicated a possibility of naloxone being "ineffective" or requiring multiple doses due to the drug's potency.
However, Dr.
Yin asserts, "There is no convincing evidence that cychlorphine is resistant to naloxone." He points to at least one published case report where a patient with a cychlorphine overdose responded to naloxone.
"As with other potent opioids, some patients may require multiple doses of naloxone.
However, this is not unique to cychlorphine, and people should absolutely administer naloxone if they suspect an overdose," he advised.
Selick further emphasized the importance of adhering to overdose protocols regardless of the suspected substance.
"Naloxone doesn’t work on an opioid; it works on the receptors of the opioids by blocking them.
When [officials] say things like naloxone doesn’t work, it makes people more likely to do nothing," he stated.
In situations where drug testing is not possible, Selick recommends individuals carry naloxone, practice staggered use (using drugs at different times so one person remains unimpaired to monitor others), and be prepared with rescue breathing and airway management techniques, which are critical in any opioid overdose scenario.
Current Prevalence and the Broader Fight Against Synthetic Drugs
Despite the media attention, cychlorphine remains relatively rare in the overall U.S. drug supply compared to fentanyl.
Between 2024 and September 2026, DEA laboratories identified only 135 exhibits of cychlorphine, in contrast to over 13,000 fentanyl exhibits tested during the July 2025 to September 2026 period.
"The medical risk is real, although fentanyl itself is still responsible for the substantially greater burden of deaths than cychlorphine or any other opioid currently," Dr.
Yin commented, putting the relative risk into perspective.
The continuous emergence of new synthetic drugs is often described as a "whack-a-mole" challenge.
Selick suggests that an overemphasis on a single drug can distract from the larger issue.
"Focusing on a specific drug ignores the trend of newer, more potent or more harmful drugs coming to the market on a regular basis," he explained.
"The solution is to end our war on drugs and make sure people are given proper medications to be able to exit the unsafe, unstable street supply with proper support." This perspective highlights the ongoing need for comprehensive harm reduction strategies and a potential reevaluation of drug policy approaches.
Note: The information provided is for informational purposes and does not constitute medical advice. Decisions regarding health and safety should always be made in consultation with qualified healthcare professionals.
Comments